MDR1, chemotherapy and chromatin remodeling

Emma K. Baker, Assam El-Osta

Research output: Contribution to journalReview ArticleResearchpeer-review

44 Citations (Scopus)


The development of multidrug resistance (MDR) in cancer can severely impede the efficacy of chemotherapy treatment. P-glycoprotein (Pgp) overexpression, encoded by the MDR1 gene, is a well-established mediator of MDR. MDR1 expression is rapidly upregulated by chemotherapeutic drugs and a number of other exogenous stimuli, however the mechanisms underlying its transcriptional regulation remain unclear. In recent years, research has indicated that chromatin accessibility, or epigenetic modifications, will play a large role in controlling the endogenous MDR1 expression state, and its response to activation stimuli. This review examines some of these studies, and discusses how new developments from the greatly expanding epigenetics field may extend to MDR1 transcriptional research.

Original languageEnglish
Pages (from-to)819-824
Number of pages6
JournalCancer Biology and Therapy
Issue number9
Publication statusPublished - 1 Jan 2004


  • Cancer
  • Chemotherapy
  • Chromatin remodeling
  • MDR1
  • Multidrug resistance

Cite this